Absci Posts $0.23 EPS Loss, $700K Revenue and $144M Cash Runway
Absci reported Q4 2025 revenue of $700K and GAAP loss per share of $0.23, with R&D spending rising to $25.3M and SG&A at $8.6M. The company posted a $5.1M settlement gain, holds $144.3M cash runway into H1 2028 and advanced ABS-201 into endometriosis trials.
1. Q4 2025 Financial Performance
Absci generated $700,000 in revenue for Q4 2025 and reported a GAAP loss of $0.23 per share, compared to a $0.25 loss in Q4 2024. R&D expenses climbed to $25.3 million from $18.4 million year-over-year, while SG&A decreased slightly to $8.6 million from $8.8 million.
2. Settlement Gain and Net Proceeds
The company recorded a $5.1 million gain on the settlement of contingent consideration, resulting in $8.7 million of unrestricted cash proceeds. This gain bolstered liquidity without dilutive financing.
3. Cash Position and Runway
As of December 31, 2025, Absci held $144.3 million in cash, cash equivalents, and marketable securities, down from $152.5 million at the previous quarter end. Management expects this balance to fund operations into the first half of 2028.
4. Pipeline Progress and Innovation
ABS-201 is showing favorable emerging safety data and has been expanded into endometriosis, targeting a second multibillion-dollar indication. The company also highlighted its de novo full-length antibody design capability and AI platform for rapid drug development, positioning it competitively despite regulatory and market risks.